title: Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees.
abstract: TNF is considered to be an intermediate factor in endotoxin-induced release of other cytokines and endotoxin-induced neutrophil degranulation. Little is known about the effect of postponed treatment with anti-TNF in primate endotoxin models. To assess the effect of delayed treatment with anti-TNF in endotoxaemia, six healthy adult chimpanzees were intravenously injected with Escherichia coli endotoxin (4 ng/kg). In three of these animals the administration of endotoxin was followed after 30 min by a bolus i.v. injection of the anti-TNF F(ab')2 fragment MAK 195F (0.1 mg/kg). Post-treatment with MAK 195F completely prevented the appearance of TNF activity in serum elicited by endotoxin, and markedly reduced the rises in the serum concentrations of IL-6 and IL-8. In addition, the endotoxin-induced increases in the type I and type II soluble TNF receptors were also profoundly inhibited by MAK 195F, suggesting that TNF is involved in the release of its own soluble receptors in endotoxaemia. Neutrophilic leucocytosis was not affected by MAK 195F. In contrast, MAK 195F did significantly abrogate neutrophil degranulation, as measured by the plasma concentrations of lactoferrin. These results indicate that treatment with anti-TNF 30 min after the administration of endotoxin is still effective in attenuating the induction of the cytokine network and of neutrophil degranulation.
authors.affiliation: Centre of Haemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, Academic Medical Centre, University of Amsterdam, The Netherlands.
authors.forename: T
authors.initials: T
authors.lastname: van der Poll
authors.forename: M
authors.initials: M
authors.lastname: Levi
authors.forename: H
authors.initials: H
authors.lastname: ten Cate
authors.forename: J
authors.initials: J
authors.lastname: Jansen
authors.forename: B J
authors.initials: BJ
authors.lastname: Biemond
authors.forename: B L
authors.initials: BL
authors.lastname: Haagmans
authors.forename: A
authors.initials: A
authors.lastname: Eerenberg
authors.forename: S J
authors.initials: SJ
authors.lastname: van Deventer
authors.forename: C E
authors.initials: CE
authors.lastname: Hack
authors.forename: J W
authors.initials: JW
authors.lastname: ten Cate
mesh_terms: D000818:Animals; D004731:Endotoxins / Q000097:blood*; D004926:Escherichia coli; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D007781:Lactoferrin / Q000097:blood; D007958:Leukocyte Count / Q000187:drug effects; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000097:blood; D009504:Neutrophils / Q000166:cytology; D002679:Pan troglodytes; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D004731:Endotoxins; D007140:Immunoglobulin Fab Fragments; D015850:Interleukin-6; D016209:Interleukin-8; D008070:Lipopolysaccharides; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D007781:Lactoferrin